secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001104659-24-121019
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA cuts workforce ~80%, pauses eseba-vec HPV16+ trial, focuses on HB-700
-----------------------------------------------------------------------------

- Workforce reduction of ~80%; implementation begins Q4 2024, substantially complete by H1 2025.
- Pauses eseba-vec program; early termination of Phase 1/2 trial for HPV16+ head and neck cancers (not due to safety or efficacy).
- Focuses on phase 1-ready HB-700 for KRAS mutated cancers (lung, colorectal, pancreatic); FDA IND clearance received Apr 2024.
- Continues HB-500 (HIV) Phase 1b trial and HB-400 (Hepatitis B) program with partner Gilead.
- Will seek partnering opportunities for the eseba-vec program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924121019/0001104659-24-121019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924121019/tm2429040d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-121019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer